Does metformin have a disease modifying effect in symptomatic knee osteoarthritis? A multicentre randomised, double-blind, placebo-controlled trial

骨关节炎(OA)是造成这种疾病负担的主要因素。目前，还没有减缓疾病进展的治疗方法。二甲双胍可能通过多种途径影响膝骨性关节炎的进展，包括减轻体重、降低血糖和血脂以及抗炎。这将是世界上第一个随机、双盲对照试验，评估二甲双胍与安慰剂对膝关节骨关节炎相关结构和临床结果的影响。

Osteoarthritis(OA) is a major contributor to this disease burden. Currently, there is no therapy that slows disease progression. Metformin may affect OA progression via multiple pathways that address the pathogenesis of knee OA, including weight loss, glucose- and lipid-lowering, and anti-inflammation. This will be the world first randomised, double-blind controlled trial, to assess the effect of metformin, compared with placebo, on knee OA-related structural and clinical outcomes